I disagree - IMO it is a big deal as it signals a shift in focus from product development (the product being BOT) to sales - in other words now there is a company, now there are four potential products, so now the focus is on selling BOT!
My hopes:
Trial momentum will be maintained.
Posited "problem" of BTX 1503 repair inhibition will be addressed.
Fast-tracking BTX 1801 to a product will be attempted.
Melanoma only studied if resources not diverted from existing work.
Funding from big pharma without cramping Botanix' style (or worth).
I disagree - IMO it is a big deal as it signals a shift in focus...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $680.2M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.499M | 3.998M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 116882 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 308907 | 13 |
View Market Depth
| Last trade - 13.17pm 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |